β-asarone suppresses HCT116 colon cancer cell proliferation and liver metastasis in part by activating the innate immune system

Oncol Lett. 2021 Jun;21(6):435. doi: 10.3892/ol.2021.12696. Epub 2021 Mar 31.

Abstract

Studies have revealed that β-asarone exerts a powerful inhibitory effect on the proliferation of human cancer cells. The authors' previous study demonstrated that β-asarone could induce LoVo colon cancer cell apoptosis in vitro and in vivo, indicating its anticancer properties. The present study aimed to determine the antineoplastic effect of β-asarone in HCT116 colon cancer cells. An in vitro proliferation assay using a real time cell analyzer demonstrated that β-asarone effectively decreased HCT116 cell proliferation in a dose-dependent manner. Bioinformatics analysis revealed that differentially expressed genes following β-asarone inhibition were involved in the 'cell cycle', 'cell division', 'cell proliferation' and 'apoptosis'. Subsequently, a xenograft assay evidenced the inhibitory effect of β-asarone on the growth of HCT116 tumors in vivo. Further detection of immune-associated cytokines and cells suggested that β-asarone might be involved in the antitumor immune response by stimulating granulocyte-colony stimulating factor and increasing the number of macrophage cells in the spleen. Additionally, a murine model of splenic-transplantation verified the strong suppressive role of β-asarone in colon cancer liver metastasis in vivo. Taken together, the results of the current study revealed that β-asarone decreased HCT116 colon cancer cell proliferation and liver metastasis potentially by activating the innate immune system, supporting the multi-system regulation theory and providing a basis for further mechanistic studies on colon cancer.

Keywords: colon cancer; immune system; liver metastasis; proliferation; β-asarone.

Grants and funding

This work was funded by The Priority Academic Program Development of Jiangsu Higher Education Institutions, the National Natural Science Foundation of China (grant no. 81202954), The Natural Science Fund of Jiangsu Province, China (grant no. BK20201499), The Peak Academic Talents Plan in Jiangsu Province Hospital of Chinese Medicine (grant no. k2018yrc25), The Six One Project in Jiangsu Province (grant no. LGY2018062), The State Administration of Traditional Chinese Medicine of the People's Republic of China (National Famous Chinese Medicine Doctor Studio grant no. 2018-119) and The National Traditional Chinese Medicine Inheritance and Innovation Platform Construction Project by National Administration of Traditional Chinese Medicine (grant no. 20085-9-5).